[go: up one dir, main page]

WO1996012791A1 - Abh humain - Google Patents

Abh humain Download PDF

Info

Publication number
WO1996012791A1
WO1996012791A1 PCT/US1994/012058 US9412058W WO9612791A1 WO 1996012791 A1 WO1996012791 A1 WO 1996012791A1 US 9412058 W US9412058 W US 9412058W WO 9612791 A1 WO9612791 A1 WO 9612791A1
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptide
habh
polynucleotide
dna
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/012058
Other languages
English (en)
Inventor
Ying-Fei Wei
Granger G. Sutton, Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Priority to JP8513858A priority Critical patent/JPH10507634A/ja
Priority to PCT/US1994/012058 priority patent/WO1996012791A1/fr
Priority to AU10411/95A priority patent/AU1041195A/en
Priority to EP95901018A priority patent/EP0788540A4/fr
Publication of WO1996012791A1 publication Critical patent/WO1996012791A1/fr
Anticipated expiration legal-status Critical
Priority to US09/023,327 priority patent/US5929225A/en
Priority to US09/296,623 priority patent/US6573360B1/en
Priority to US10/322,780 priority patent/US20030153738A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Definitions

  • the tagA gene has been mapped to an E. Coli chromosome and controls a constitutive enzyme 3-methyladenine-DNA glycosylase I that releases 3-methyladenine from alkylated DNA (Karran, P. et al. , Nature (London), 296:770-773 (1982)).
  • the alkA gene has also been mapped and it too controls an inducible enzyme, 3-methyladenine-DNA glycosylase II, which catalyzes the liberation of 3-methyladenine, 3-methylguanine, and 7-methylguanine from the DNA (Evensen, G. and Seeberg, E., Nature (London), 296:773-775 (1982).
  • a novel mature polypeptide which is hABH, as well as fragments, analogs and derivatives thereof.
  • the polypeptide of the present invention is of human origin.
  • polynucleotides DNA or RNA which encode such polypeptides.
  • the polynucleotide which encodes for the mature polypeptide of Figure 1 or for the mature polypeptide encoded by the deposited cDNA may include: only the coding sequence for the mature polypeptide; the coding sequence for the mature polypeptide and additional coding sequence such as a leader or secretory sequence or a proprotein sequence; the coding sequence for the mature polypeptide (and optionally additional coding sequence) and non-coding sequence, such as intron ⁇ or non-coding sequence 5' and/or 3' of the coding sequence for the mature polypeptide.
  • the present invention includes polynucleotides encoding the same mature polypeptide as shown in Figure 1 or the same mature polypeptide encoded by the cDNA of the deposited clone as well as variants of such polynucleotides which variants encode for a fragment, derivative or analog of the polypeptide of Figure 1 or the polypeptide encoded by the cDNA of the deposited clone.
  • Such nucleotide variants include deletion variants, substitution variants and addition or insertion variants.
  • the present invention also provides a diagnostic assay for detecting mutated hABH genes, which is indicative of a susceptibility to mutation of DNA by various agents, such as chemical mutation.
  • a diagnostic assay for detecting mutated hABH genes, which is indicative of a susceptibility to mutation of DNA by various agents, such as chemical mutation.
  • an assay is the RT- PCR method.
  • RT-PCR Reverse Transcriptase Polymerase Chain Reaction
  • the RNA encoding hABH is isolated from the total cellular RNA removed from a cell sample.
  • the coding region of the RT-PCR products are then sequenced and compared to the hABH gene to detect mutations.
  • oligonucleotide probes may be prepared which are highly specific for the mRNA to be detected.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne deux substances de provenance humaine, un polypeptide hABH et de l'ADN (ARN) codant pour ce polypeptide ainsi qu'un procédé permettant de le fabriquer par génie génétique. L'invention prévoit aussi des méthodes visant à utiliser le polypeptide dans le traitement des mutations et des maladies découlant d'un ADN endommagé, comme par exemple, un cancer. L'invention porte également sur des antagonistes de ces polypeptides et sur leur application comme thérapeutique permettant de renforcer la chimiothérapie des cellules cancéreuses.
PCT/US1994/012058 1994-10-21 1994-10-21 Abh humain Ceased WO1996012791A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP8513858A JPH10507634A (ja) 1994-10-21 1994-10-21 ヒトａｂｈ
PCT/US1994/012058 WO1996012791A1 (fr) 1994-10-21 1994-10-21 Abh humain
AU10411/95A AU1041195A (en) 1994-10-21 1994-10-21 Human abh
EP95901018A EP0788540A4 (fr) 1994-10-21 1994-10-21 Abh humain
US09/023,327 US5929225A (en) 1994-10-21 1998-02-13 Human ABH
US09/296,623 US6573360B1 (en) 1994-10-21 1999-04-23 Human ABH
US10/322,780 US20030153738A1 (en) 1994-10-21 2002-12-19 Human ABH

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/012058 WO1996012791A1 (fr) 1994-10-21 1994-10-21 Abh humain

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08/463,975 Continuation-In-Part US5618717A (en) 1994-10-21 1995-06-05 DNA encoding human AlkB
US09/023,327 Continuation-In-Part US5929225A (en) 1994-10-21 1998-02-13 Human ABH

Publications (1)

Publication Number Publication Date
WO1996012791A1 true WO1996012791A1 (fr) 1996-05-02

Family

ID=22243169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/012058 Ceased WO1996012791A1 (fr) 1994-10-21 1994-10-21 Abh humain

Country Status (4)

Country Link
EP (1) EP0788540A4 (fr)
JP (1) JPH10507634A (fr)
AU (1) AU1041195A (fr)
WO (1) WO1996012791A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019959A3 (fr) * 2002-08-30 2005-01-06 Imp Cancer Res Technology Enzymes de reparation de l'adn

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007000002A (ja) * 2003-07-16 2007-01-11 Genecare Research Institute Co Ltd アルキル化薬感受性を上昇させる方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANNUAL REVIEW OF BIOCHEMISTRY, Volume 57, issued 1988, T. LINDAHL et al., "Regulation and Expression of the Adaptive Response to Alkylating Agents", pages 133-157. *
JOURNAL OF BACTERIOLOGY, Volume 176, No. 20, issued October 1994, B.J. CHEN et al., "The Escherichia Coli alkB Protein Protects Human Cells Against Alkylation-Induced Toxicity", pages 6255-6261. *
JOURNAL OF BIOLOGICAL CHEMISTRY, Volume 261, No. 33, issued 25 November 1986, H. KONDO et al., "Structure and Expression of the alkB Gene of Eschericha Coli Related to the Repair of Alkylated DNA", pages 15772-15777. *
MOLECULAR AND GENERAL GENETICS, Volume 198, issued 1985, H. KATAOKA et al., "Molecular Cloning and Characterization of the alkB Gene of Escherichia Coli", pages 263-269. *
PROC. NATL. ACAD. SCI. U.S.A., Volume 86, issued October 1989, J. CHEN et al., "Cloning a Eukaryotic DNA Glycosylase Repair Gene by the Suppression of a DNA Repair Defect in Escherichia Coli", pages 7961-7965. *
See also references of EP0788540A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019959A3 (fr) * 2002-08-30 2005-01-06 Imp Cancer Res Technology Enzymes de reparation de l'adn

Also Published As

Publication number Publication date
EP0788540A4 (fr) 2000-01-12
AU1041195A (en) 1996-05-15
EP0788540A1 (fr) 1997-08-13
JPH10507634A (ja) 1998-07-28

Similar Documents

Publication Publication Date Title
US6538121B1 (en) Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
US6284504B1 (en) Human DNA ligase III
US5928924A (en) Human geranylgeranyl pyrophosphate synthetase
US5723311A (en) Human DNA topoisomerase I α
US6573360B1 (en) Human ABH
AU683286B2 (en) Superoxide dismutase-4
US5759854A (en) Neurotransmitter transporter
WO1995031537A9 (fr) OXALYL-CoA DECARBOXYLASE HUMAINE
US6455274B1 (en) Human DNA Ligase IV
EP0788540A1 (fr) Abh humain
US7416855B2 (en) Immunoassay methods for detecting interleukin-1 β converting enzyme like apoptosis protease-3
EP0881294A2 (fr) HOEFCC11, variante d'épissure de HAS2
US6255077B1 (en) Human DNA topoisomerase I α
WO1996021736A1 (fr) Geranylgeranyle pyrophosphate synthetase humaine
US5859200A (en) Human amine transporter
US20060234342A1 (en) Human DNA topoisomerase I alpha
US20020065393A1 (en) Human hypoxanthine- (guanine) phosphoribosy1 transferase-2
WO1996021724A1 (fr) Desoxycytidine kinase 2 humaine
JPH11506309A (ja) ヒトアミン輸送体
US20030157103A1 (en) Human amine transporter antibodies
AU1174795A (en) Human DNA ligase IV
JP2002176994A (ja) ヒトａｂｈ
JP2002020313A (ja) ヒトｄｎａトポイソメラーゼｉ−アルファ
JP2002330795A (ja) ヒトアミン輸送体

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP KR NZ US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995901018

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995901018

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995901018

Country of ref document: EP